{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-071704","form_type":"8-K","ticker":"LGVN","cik":"0001721484","company_name":"Longeveron Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.880621+00:00","generated_at":"2026-06-21T20:42:12.422992+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Longeveron reports Q3 2022 net loss of $5.2M; completes Phase 2a Alzheimer's enrollment","bullets":["Net loss of $5.2M ($0.25 per share) vs $4.9M in Q3 2021; revenue up to $0.3M from $0.2M.","Completed enrollment in Phase 2a Lomecel-B trial for mild Alzheimer's Disease; topline results expected 2024.","FDA granted Fast Track Designation for Lomecel-B in Hypoplastic Left Heart Syndrome (HLHS).","Cash and short-term investments of $22.3M; expected runway into first half 2024.","R&D expenses increased 45% to $2.9M; G&A decreased 31% to $2.1M."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-071704","json":"https://secwatch.observer/filing/0001213900-22-071704.json","markdown":"https://secwatch.observer/filing/0001213900-22-071704.md","text":"https://secwatch.observer/filing/0001213900-22-071704.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1721484/000121390022071704/0001213900-22-071704-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1721484/000121390022071704/ea168423-8k_longeveron.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:42:12.422992+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4ef08ab64ed322974060052e92cf78aaa98a6112","claim":"Longeveron Inc. reported third quarter ended September 30, 2022 results: revenue $0.3 million.","evidence_excerpt":"Revenue for the third quarters of 2022 and 2021 was $0.3 million and $0.2 million, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1721484/000121390022071704/0001213900-22-071704-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$0.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}